Latanoprost Aspire Pharma

Latanoprost, the active ingredient in Latanoprost Aspire Pharma, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Latanoprost Aspire Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is used to manage conditions that involve elevated intra‑ocular pressure within the glaucoma disease family. - Open‑angle glaucoma: reduces intra‑ocular pressure to slow optic‑nerve damage and visual field loss. - Ocular hypertension: lowers pressure to prevent conversion to glaucoma. - Elevated intra‑ocular pressure: maintains target pressure levels to protect the optic nerve.

Latanoprost may cause ocular and systemic reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris darkening: gradual pigmentation change. - Eye irritation: burning or stinging sensation. - Blurred vision: temporary visual disturbance. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Uveitis: inflammation of the uveal tract. - Corneal edema: swelling of the cornea affecting clarity. - Paradoxical rise in intra‑ocular pressure. - Ocular infection: signs of bacterial or fungal involvement. - Vision loss: sudden decrease in visual acuity.

Before initiating therapy, consider the following safety measures. - Monitor IOP: regular intra‑ocular pressure checks to assess efficacy. - Assess ocular surface: evaluate for pre‑existing inflammation or infection. - Pregnancy and lactation: use only if the potential benefit outweighs risk, as safety data are limited. - Concomitant eye medications: evaluate for additive ocular effects. - Storage: Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost may interact with other ophthalmic agents, altering efficacy or safety.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analogs: may increase risk of ocular irritation. - Combination with systemic carbonic anhydrase inhibitors: can lead to excessive IOP reduction. - Use with ocular corticosteroids: may diminish steroid efficacy.

Moderate Interactions (Monitor Closely): - Nonsteroidal anti‑inflammatory eye drops: may affect prostaglandin pathways. - Beta‑blocker eye drops: monitor for additive IOP‑lowering effect. - Systemic NSAIDs: potential alteration of prostaglandin metabolism.